Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Somogyi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Chest|March 11, 2026
ResponseThomas James Altree, Andrew Somogyi, David Currow, et al.
Pain Reports|June 17, 2025
Establishing the patient acceptable symptom state for patient-reported pain outcomes 6 months after breast cancer surgeryMatthew Kang, David Rice, Nuala Helsby, et al.
The Australian and New Zealand Journal of Psychiatry|May 11, 2013
Ketamine as a new treatment for depression: a review of its efficacy and adverse effectsNatalie Katalinic, Rosalyn Lai, Andrew Somogyi, et al.
British Journal of Clinical Pharmacology|December 15, 2010
Editors' pick 2010Yoon K Loke, Albert Ferro, Lionel D Lewis, et al.
British Journal of Clinical Pharmacology|December 18, 2012
Editors' pick 2012Lionel D Lewis, Andrew Somogyi, Yoon K Loke, et al.
British Journal of Clinical Pharmacology|January 24, 2014
Editors' pick 2013Albert Ferro, Yoon K Loke, Lionel D Lewis, et al.
Clinical Pharmacology and Therapeutics|March 22, 2002
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transportersHartmut Glaeser, Siegfried Drescher, Heiko van der Kuip, et al.
Chest|December 15, 2024
The Effects of Low-Dose Morphine on Sleep and Breathlessness in COPD: A Randomized TrialThomas J Altree, Alison J Pinczel, Barbara Toson, et al.
Journal of Affective Disorders|February 20, 2024
Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS)Donel M Martin, Anna J Harvey, Bernard Baune, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 6, 2026
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS studyNick Glozier, Richard Morris, Elizabeth Stratton, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Chest|March 11, 2026
ResponseThomas James Altree, Andrew Somogyi, David Currow, et al.
Pain Reports|June 17, 2025
Establishing the patient acceptable symptom state for patient-reported pain outcomes 6 months after breast cancer surgeryMatthew Kang, David Rice, Nuala Helsby, et al.
The Australian and New Zealand Journal of Psychiatry|May 11, 2013
Ketamine as a new treatment for depression: a review of its efficacy and adverse effectsNatalie Katalinic, Rosalyn Lai, Andrew Somogyi, et al.
British Journal of Clinical Pharmacology|December 15, 2010
Editors' pick 2010Yoon K Loke, Albert Ferro, Lionel D Lewis, et al.
British Journal of Clinical Pharmacology|December 18, 2012
Editors' pick 2012Lionel D Lewis, Andrew Somogyi, Yoon K Loke, et al.
British Journal of Clinical Pharmacology|January 24, 2014
Editors' pick 2013Albert Ferro, Yoon K Loke, Lionel D Lewis, et al.
Clinical Pharmacology and Therapeutics|March 22, 2002
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transportersHartmut Glaeser, Siegfried Drescher, Heiko van der Kuip, et al.
Chest|December 15, 2024
The Effects of Low-Dose Morphine on Sleep and Breathlessness in COPD: A Randomized TrialThomas J Altree, Alison J Pinczel, Barbara Toson, et al.
Journal of Affective Disorders|February 20, 2024
Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS)Donel M Martin, Anna J Harvey, Bernard Baune, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 6, 2026
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS studyNick Glozier, Richard Morris, Elizabeth Stratton, et al.
Pageof 1